financetom
Business
financetom
/
Business
/
Holiday Inn owner IHG confident US domestic demand will deliver profit growth (May 8)
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Holiday Inn owner IHG confident US domestic demand will deliver profit growth (May 8)
May 26, 2025 5:01 AM

(This May 8 story has been corrected to remove the extraneous word 'pounds' in paragraph 11)

By Raechel Thankam Job

(Reuters) - Holiday Inn owner InterContinental Hotels Group ( IHG ) said on Thursday it is on track to meet analysts' profit expectations after reporting growth in U.S. room revenues that outpaced rivals. The United States is IHG's largest market, which faces heightened recession risks due to a global trade war sparked by President Donald Trump's tariffs, prompting IHG's peers Marriott and Hilton to cut their full-year guidance.

IHG reported 3.5% growth in U.S. room revenue for the three months ended March 31 on Thursday, compared with a 1.9% fall last year. Its growth outpaced Hilton's performance in the region as well as Marriott's ( MAR ) combined growth in U.S and Canada. IHG said its on-the-books global revenue growth had continued into the second quarter, while noting some softening of forward economic indicators. The group, known for its budget-friendly Holiday Inn and Avid Hotel brands, is banking on U.S. domestic demand to support growth as international travel to the U.S. cools. A rebound in the U.S. market has helped it counter sluggish demand in China. However, the hotel operator expects fiscal 2025 revenue per available room (RevPAR) to come a little below analysts' consensus of 2.3%, chief financial officer Michael Glover said in a call with analysts. "IHG is a largely mid-market franchise hotel business, and we expect it would be resilient in an economic slowdown" Peel Hunt analysts said in a note, adding that they believe its shares are undervalued.

As of Wednesday's close, IHG's shares have slumped 13.5% in 2025, compared to Hilton's 2.2% dip and Marriott's ( MAR ) 8.2% drop. Shares in the London-listed company were up 2.3% at 8,808 pence at 1352 London time.    Analysts expect IHG to report core earnings of $1.32 billion for the fiscal year 2025 according to a company compiled poll.

In 2024, the company reported $1.19 billion in core earnings.  

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CytoSorbents Files Appeal With FDA Over Denial of Device
CytoSorbents Files Appeal With FDA Over Denial of Device
Jun 24, 2025
07:46 AM EDT, 06/24/2025 (MT Newswires) -- CytoSorbents ( CTSO ) said Tuesday it filed an appeal with the US Food and Drug Administration over the denial of its DrugSorb-ATR device on April 25. The appeal will allow CytoSorbents ( CTSO ) to engage with the agency in a process that includes a formal hearing, where it will try to...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Nektar Therapeutics' experimental eczema drug meets main goal of mid-stage trial
Nektar Therapeutics' experimental eczema drug meets main goal of mid-stage trial
Jun 24, 2025
June 24 (Reuters) - Nektar Therapeutics ( NKTR ) said on Tuesday its experimental eczema drug had met the main goal of a mid-stage study. In the 393-patient trial, drug candidate rezpegaldesleukin showed a reduction in the severity of eczema measured with a widely used index. Eczema, also known as atopic dermatitis, is a chronic skin condition that causes inflammation,...
Tilray Receives Italy's Authorization to Distribute Medical Cannabis Flower for Therapeutic Use
Tilray Receives Italy's Authorization to Distribute Medical Cannabis Flower for Therapeutic Use
Jun 24, 2025
07:45 AM EDT, 06/24/2025 (MT Newswires) -- Tilray Brands ( TLRY ) on Tuesday said it is introducing three new medical cannabis flower varieties in Italy after receiving the go-ahead from the country's health ministry. The products will be available for distribution through pharmacies across Italy beginning this month. Tilray is the first company to recevie authorization to import and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved